Efficacy, Safety, Tolerability of AXA1125 in Fatigue Predominant PASC
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This study will compare the effects of AXA1125, an orally active mixture of amino acids,
compared to placebo, on improving muscle function (metabolism) following moderate exercise in
subjects with fatigue-Predominant Post-Acute Sequelae of SARS-CoV-2 as well as the safety and
tolerability of AXA1125. Subjects will take one dose of AXA1125 or a placebo twice daily for
28 days.